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Abstract 
Objective 
To explore the relationship between baseline resting heart rate and outcomes in patients 
with chronic heart failure (HF) according to baseline left ventricular ejection fraction (LVEF) 
and cardiac rhythm. 
Background 
Elevated resting heart rate is associated with worse outcomes in patients with HF and 
reduced LVEF. Whether this association is also found in patients with HF and preserved LVEF 
is uncertain, as is the predictive value of heart rate in patients in atrial fibrillation (AF). 
Methods 
Patients enrolled in the Candesartan in Heart failure: Assessment of Reduction in Mortality 
and morbidity (CHARM) Program were divided into groups by tertiles of baseline heart rate. 
Cox proportional hazard models were used to investigate the association between heart rate 
and pre-specified outcomes in the overall population as well as in subgroups defined 
according to LVEF (≤40% vs. >40%) and presence (or absence) of AF at baseline.  
Results 
After adjusting for predictors of poor prognosis, patients in the highest heart rate tertile had 
worse outcomes when compared with those in the lowest heart rate group (e.g. for the 
composite of cardiovascular death or HF hospitalization HR=1.23, 95% CI 1.11-1.36, 
p<0.001). The relationship between heart rate and outcomes was similar across LVEF 
categories and was not influenced by beta-blocker use (p value for interaction >0.10 for both 
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endpoints). However, amongst patients in AF at baseline, heart rate had no predictive value 
(p value for interaction <0.001). 
Conclusions 
Resting heart rate is an important predictor of outcome in patients with stable chronic HF 
without AF, regardless of LVEF or beta-blocker use.  
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Introduction 
 
Elevated resting heart rate is an established risk factor for cardiovascular mortality and 
morbidity in a variety of cardiovascular diseases (1). In patients with reduced left ventricular 
ejection fraction (LVEF), with or without signs or symptoms of heart failure (HF), high heart 
rate has been associated with worse outcomes, independently of other known risk factors 
(2-6). Several pathophysiologic mechanisms including blunting of the force-frequency 
relationship, the induction of myocardial ischemia, precipitation of rhythm disturbances and 
acceleration of atherosclerosis have been proposed to explain the association between 
higher heart rate and worse outcomes in patients with HF (1,7). Higher heart rate may also 
be a marker of greater neurohumoral activation. The recent findings of the Systolic Heart 
failure treatment with the If inhibitor ivabradine Trial (SHIFT), have confirmed the 
importance of heart rate in the pathophysiology of HF with reduced LVEF and have 
suggested heart rate reduction per se as a mechanism responsible for improvement of 
clinical outcomes (8). 
Whether higher resting heart rate also has prognostic importance in patients with HF and 
preserved LVEF, representing a third to a half of the patients with HF (9,10), is less well 
documented. Furthermore, little is known about the relationship between heart rate and 
outcomes in patients with atrial fibrillation (AF), the prevalence of which increases in parallel 
with the severity of HF (11). The Candesartan in Heart Failure: Assessment of Reduction in 
Mortality and morbidity (CHARM) Program, enrolled 7599 patients with a clinical diagnosis 
of HF, irrespective of LVEF, and assessed the effect of the angiotensin receptor blocker 
candesartan on cardiovascular mortality and morbidity (12). The main aims of this analysis 
were to examine the relationship between resting heart rate at baseline and fatal and 
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nonfatal cardiovascular outcomes and all-cause mortality in a broad spectrum of patients 
with HF, and to determine whether the relationship between heart rate and outcomes was 
influenced by LVEF or underlying cardiac rhythm. 
 
 
Methods 
 
The CHARM Program 
The design, baseline findings and overall results of the CHARM Program have been 
previously reported in detail (12-14).  In brief, 7599 patients with at least 4 weeks duration 
of symptomatic HF [New York Heart Association (NYHA) class II-IV] receiving standard 
therapy, were enrolled into one of three component clinical trials according to LVEF and 
angiotensin converting enzyme inhibitor (ACE-I) treatment: CHARM-Alternative (n=2028, 
LVEF ≤40% and not receiving an ACE-I due to previous intolerance), CHARM-Added (n=2548, 
LVEF ≤40% receiving ACE-I treatment) and CHARM-Preserved (n=3023, LVEF >40%) (15-17). 
Important exclusion criteria were serum creatinine 3mg/dL (265 µmol/L) or more, serum 
potassium 5.5 mmol/L or more, known bilateral renal artery stenosis, symptomatic 
hypotension, critical aortic or mitral stenosis, or recent (in the previous 4 weeks) myocardial 
infarction, stroke, or heart surgery. Within each of the component trials, patients were 
randomly allocated to candesartan or matching placebo, initiated at 4 mg or 8 mg (at the 
investigator’s discretion) once daily at the enrollment visit. The dose was increased towards 
the target dose (32 mg once daily) in a stepwise fashion as tolerated, but not faster than 
every 2 weeks. Because the rate of recruitment varied between the CHARM trials, follow-up 
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ranged from a median of 34 months in CHARM-Alternative and 37 months in CHARM-
Preserved to 41 months in CHARM-Added (38 months in the overall CHARM Program). 
 
Baseline heart rate measurement and outcomes evaluated 
In accordance with the protocol and standard operating procedures, all patients enrolled in 
the CHARM Program had baseline heart rate measured by the site investigator at the 
randomization visit. After a resting period of 5 minutes, heart rate was either assessed by 
palpation for at least 30 seconds or from auscultation of the heart or from 
electrocardiogram (ECG). In addition, a 12-lead ECG was recorded in all patients and 
interpreted by investigators at each participating center using a structured report taking into 
account, amongst others, the presence or absence of atrial fibrillation. In patients for whom 
both pieces of information were available, we examined the association between baseline 
resting heart rate, heart rhythm (determined by the baseline ECG) and all-cause death (the 
primary outcome of the entire CHARM Program) and the composite outcome of 
cardiovascular death or hospitalization for the management of worsening HF (the primary 
outcome of each component trial). All endpoints were adjudicated in a blinded fashion. 
Deaths were considered to be cardiovascular unless another clear cause was apparent. 
Treatment in hospital for worsening HF was defined as an unplanned admission that was 
necessitated by HF and required intravenous diuretics. 
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Statistical analysis 
To illustrate the relationship between resting heart rate and baseline characteristics, we 
divided patients into groups by tertiles of heart rate. Tertiles were chosen according to the 
resting heart rate distribution at baseline. Each of these heart rate bands was centered 
round a multiple of 10, because we observed a substantial “digit preference” for investigator 
reported heart rate. Differences in baseline characteristics across tertiles of baseline heart 
rate were assessed with a test for trend by means of variance weighted least square 
regression for continuous variables and with a nonparametric test for trend (18) for 
categorical variables in the overall CHARM population, as well as in subgroups defined 
according to LVEF (i.e. reduced vs. preserved) and heart rhythm (presence or absence of AF). 
Kaplan-Meier survival analysis stratified according to tertiles of baseline heart rate for death 
from any cause and for the composite of cardiovascular death or hospitalization for 
worsening heart failure were determined and presented as event curves, compared by 
means of log-rank test. Incidence rates were calculated per 100 person-years. The 
association between baseline heart rate and risk was assessed with either univariate and 
multivariable Cox proportional-hazard models, fitting heart rate both as a continuous 
variable (hazard ratio for each 10-beats per minute [bpm] change in heart rate) and as a 
categorical (hazard ratio calculated for the lowest tertile as reference). Multivariable analysis 
adjusted for the 10 strongest predictors of outcome, as expressed by decreasing χ2 statistic, 
previously identified in the CHARM program (19): age (years), LVEF, diabetes, previous HF 
hospitalization, NYHA class, body mass index (BMI), diastolic blood pressure (DBP), gender, 
radiologic cardiomegaly (defined as a cardiothoracic ratio ≥ 0.5 at chest X-ray) and 
candesartan treatment. In addition, beta-blocker use at baseline was added into the model 
because of the direct heart rate-lowering effect of beta-blockers and because of their 
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beneficial effect on morbidity and mortality in patients with HF. The proportional hazards 
assumption was checked both graphically and by means of scaled Schoenfeld residuals. 
Interaction testing was used to assess whether the relation between baseline heart rate and 
outcome was modified by LVEF (modeled either as a continuous variable or categorized 
≤40% vs. >40%) and beta-blocker use at randomization. Formal interaction testing was also 
used to ascertain whether the relation between baseline heart rate and outcomes differed in 
specific subgroups: patients with and without AF, diabetic and non diabetic patients, current 
smokers and non smokers. Continuous variables were expressed as medians and 
interquartile ranges (IQR) and categorical variables as counts and percentages. All p-values 
were two sided, and p<0.05 was used to determine statistical significance, except for tests 
for interaction for which p<0.10 was used. Analyses were all based on intention-to-treat and 
were performed with STATA, version 11.2 (StataCorp LP, College Station, TX, USA). 
 
 
Results 
 
Baseline characteristics  
Information about baseline resting heart rate and rhythm were available for 7597 (99.9%) 
participants in the CHARM Program and the median heart rate overall was 72 bpm (IQR 64, 
80).  Baseline demographic and clinical characteristics in the overall CHARM population 
grouped by tertiles of baseline heart rate are shown in Table 1. Patients with a higher heart 
rate were younger and more often female, diabetic or a current smoker. A higher resting 
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heart rate was also associated with lower LVEF and with higher DBP and NYHA class. More 
patients in the highest heart rate tertile had been previously admitted to hospital because of 
HF decompensation, compared with patients in the two lower heart rate tertiles. By 
contrast, patients in the highest heart rate group were less likely to have suffered from 
myocardial infarction compared with patients in the other groups. The proportion of 
patients treated with a beta-blocker decreased as heart rate increased, whereas, the use of a 
diuretic, spironolactone and digoxin increased with increasing heart rate. In patients with 
reduced and preserved LVEF, as well as in those without AF at baseline, the distribution of 
baseline characteristics across tertiles of heart rate was similar to what was observed in the 
overall population (Table 2 and 3). However, some of the differences between heart rate 
tertiles seen in these other subgroups were not present in patients with AF (Table 3). In 
particular, there was no gradient in LVEF, NYHA class or history of diabetes. There was also 
no gradient in history of hospitalization for HF or in use of diuretics or digoxin, although the 
frequency of each of these was higher in patients with AF (irrespective of heart rate) than in 
patients without AF (Table 3). 
 
Baseline heart rate and all-cause mortality 
In the overall CHARM population, during a median follow-up of 37.7 months, 1831 patients 
(24.1%) died. Individuals with a higher heart rate at baseline had a greater risk of death from 
any cause compared with those with a lower heart rate (overall log-rank test p value <0.001, 
Figure 1A). Beta-blocker use at randomization was associated with a lower risk of death but 
did not change the association between heart rate and mortality (p for interaction = 0.55, 
Figure 2A). The relationship between heart rate and mortality (and cardiovascular death or 
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HF hospitalization) was also observed when beta-blocker dose was taken into consideration 
(higher heart rate was associated with worse outcomes whether or not patients were taking 
≥50% of recommended dose or ≥median dose). The absolute death rate/100 patient-years of 
follow up in patients with reduced LVEF was approximately double that in patients with 
preserved LVEF but a concordant increment in death rates was seen with increasing heart 
rate in each of the two LVEF categories (Table 4 and Figure 3A). Similarly, the unadjusted risk 
of death showed a concordant increase across tertiles of heart rate irrespective of LVEF (p 
for interaction with continuous LVEF = 0.80; with categorical LVEF = 0.68; Figure 4A); the 
findings were similar if LVEF was dichotomized at 50% rather than 40% in the categorical 
analysis (and this was also true for the outcome of cardiovascular death or HF 
hospitalization). The association between higher heart rate and the risk of death remained 
significant in a multivariable model that adjusted for the covariates listed in the Methods in 
both LVEF subgroups (Table 4); adding baseline treatment including ACE-inhibitors, beta-
blockers, diuretics, spironolactone and digitalis glycosides to the multivariable model did not 
change this finding. Treating baseline heart rate as a linear continuous variable, for each 
additional 10-beat increase there was a 6% and 5% adjusted risk accrual in patients with 
reduced and preserved LVEF, respectively (Table 4).  
When heart rhythm at randomization was taken into account, the association between 
higher heart rate and the risk of death was confirmed in patients without AF but not in those 
with AF at baseline  (p for interaction <0.001; Table 4 and Figure 5A). Modeling heart rate as 
a linear continuous variable, a 10-beat increase in heart rate was associated with a 8% 
increase in the risk of death in patients without AF but no significant increase in risk was 
observed in patients with AF (Table 4). The association between a higher baseline heart rate 
and a higher risk of death was observed regardless of diabetic and smoking status (p for 
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interaction between heart rate and diabetes = 0.47; p for interaction between heart rate and 
smoking status = 0.33). 
 
Baseline heart rate and cardiovascular death or hospitalization for worsening heart failure 
Patients with a higher heart rate at baseline had a higher incidence of the composite 
outcome of cardiovascular death or HF hospitalization (overall Log-rank test p value <0.001, 
Figure 1B). The association between higher heart rate and the risk of the composite outcome 
was observed independently of beta-blocker use at baseline (p for interaction = 0.77, Figure 
2B). A similar pattern of increase in event rate across heart rate tertiles was seen in both the 
reduced and preserved LVEF groups (Table 4 and Figure 3B). This finding was confirmed in 
the univariate and multivariable analysis, where an increase in the risk of cardiovascular 
death or HF hospitalization was observed with increasing heart rate regardless of baseline 
LVEF (p for interaction with continuous LVEF = 0.88; with categorical LVEF = 0.96, Figure 4B, 
Table 4). Adding baseline treatment including ACE-inhibitors, beta-blockers, diuretics, 
spironolactone and digitalis glycosides to the multivariable model did not change this 
finding. Using baseline heart rate as a continuous variable, a 10-beat increase in heart rate 
was associated with a 7% and with a 6% increase in the risk of the composite endpoint in 
patients with reduced and preserved LVEF, respectively (Table 4).  
The prognostic importance of heart rate was confirmed in patients without AF at baseline 
either modeling heart rate as a categorical (adjusted HR 1.28, CI 1.14 – 1.44 for patients in 
the highest heart rate tertile of heart rate) or as a continuous variable (adjusted HR 1.10, CI 
1.06 – 1.13 for each 10-beat increase in heart rate). By contrast, in patients with AF at 
baseline, there was no association between heart rate and the risk of the composite 
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outcome (p value for interaction between heart rate and the presence of AF <0.001; Table 4 
and Figure 5B). This conclusion was not altered by adding digoxin to the multivariable model. 
Although higher event rates were observed with increasing heart rate, the association 
between a higher heart rate and a higher risk of cardiovascular death or HF hospitalization 
seemed stronger in nondiabetics than in diabetics (p for interaction between heart rate and 
diabetes = 0.01) A possible interaction between heart rate and current smoking was also 
observed (p = 0.07). 
 
Effect of candesartan and baseline heart rate  
Although candesartan did not reduce mortality overall in the CHARM Program, there was a 
nominally significant interaction between heart rate at baseline and the effect of 
candesartan on all-cause mortality (p value for interaction = 0.04), with an apparent 
reduction in mortality only in patients in the highest heart rate-tertile (data not shown). This 
interaction was not seen for the composite of cardiovascular death or heart failure 
hospitalization (p=0.24) for which there were many more events and which was reduced, 
overall, by candesartan.  
 
 
Discussion 
The CHARM dataset provided a unique opportunity to examine the relationship between 
baseline resting heart rate and outcomes in a large cohort of patients with a wide range of 
LVEF and receiving contemporary management for symptomatic HF.  Our analysis confirmed 
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the predictive value of resting heart rate in patients with HF and sinus rhythm, for both the 
composite outcome of cardiovascular death or heart failure hospitalization and all-cause 
mortality. The greater risk of events in patients with higher heart rate was observed across 
the full spectrum of LVEF and persisted even after adjustment for other recognized 
predictors of mortality and morbidity. Moreover, the relationship between heart rate and 
outcomes in patients with sinus rhythm was not modified by the use of beta-blockers at 
baseline. Interestingly, however, higher heart rate was not related to outcome in patients 
with AF.   
 
 Heart rate as a risk marker in patients with HF 
Certain variables previously reported to be associated with worse outcomes in HF (e.g. 
diabetes, higher NYHA class, lower LVEF and a history of HF hospitalization) were more 
frequent in patients with a higher heart rate at baseline, but other variables associated with 
a better outcome were also more common in patients with a higher heart rate (e.g. younger 
age, female sex and lower frequency of prior myocardial infarction). The baseline use of 
beta-blockers was also lower in patients with higher heart rate, possibly because these 
individuals had worse overall clinical status or less indications for beta-blockers. In addition, 
higher heart rate may also reflect unmeasured variance such as neuroendocrine activity, 
particularly sympathetic activity (or sympathetic-parasympathetic imbalance). However, 
heart rate remained an independent predictor of outcome in a multivariable analysis taking 
into account these imbalances and no interaction between baseline heart rate and beta-
blocker use was observed. 
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Association between heart rate and outcomes across the continuum of LVEF 
We found no interaction between resting heart rate and LVEF, indicating that the value of 
elevated heart rate in predicting worse outcomes was independent of baseline left 
ventricular systolic function in patients with HF. Despite the epidemiologic importance of HF 
with preserved LVEF, only two other studies have examined the association between 
baseline heart rate and outcomes in this sub-group of patients. In a post hoc analysis of the 
Digitalis Investigation Group (DIG) Trial, a higher heart rate was associated with a greater risk 
of HF hospitalization both in patients with reduced and preserved LVEF. However, an 
association between higher heart rate and higher mortality was only seen in patients with a 
reduced LVEF (20). The discrepancy between these findings and ours warrants further 
investigations but may be due to differences between the studies. Beta-blockers were not 
used to treat HF at the time of DIG and patients in that trial had a LVEF greater than 45% 
(compared with 40% in CHARM).  Perhaps, most importantly, the DIG preserved LVEF 
ancillary trial was a much smaller that CHARM-Preserved, resulting in considerably fewer 
deaths in this subset of patients in DIG (i.e. 231 versus 364 in CHARM-Preserved), and 
greater statistical power in CHARM-Preserved. Nevertheless, further examination of the 
relationship between heart rate and outcomes in HF with preserved LVEF is needed before 
any definitive conclusion can be drawn. Recently, Kapoor et al. reported that high resting 
heart rate was associated with worse survival among 685 consecutive patients with 
preserved systolic function (with 278 deaths overall) (21). This cohort was, however, unusual 
in that 97% of the patients were male. 
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The prognostic value of heart rate according to baseline cardiac rhythm 
An interesting finding of our analysis was the lack of predictive value of higher heart rate in 
patients with AF at baseline. Although the number of patients and events was much smaller 
in the AF subgroup, the highly significant interaction between heart rhythm and the 
relationship between heart rate and outcomes suggests that this finding is a true one. 
Moreover, a similar observation was made in a cohort of patients with acute heart failure, in 
which a higher heart rate was associated with a significantly lower all-cause and 
cardiovascular mortality in those with AF (22). In another study of patients with moderate to 
severe chronic HF and concomitant AF, a lower heart rate at baseline was associated with a 
worse prognosis (23). The explanation for this apparently paradoxical finding in patients with 
AF (compared with those in sinus rhythm) is uncertain. Whilst in patients with HF and in 
sinus rhythm a higher heart rate could be a marker of greater neurohumoral activation (24) 
or significant autonomic impairment (25) this may not be so in those with AF. Furthermore, 
systematic underestimation of the ventricular rate may have occurred in patients with AF 
when the rate was assessed by palpation or auscultation. Conversely, a true low ventricular 
rate may indicate conducting system disease, itself a poor prognostic feature. In patients 
with AF, a higher ventricular rate may be a compensatory response to the reduction in 
cardiac output due to loss of effective atrial contraction (26).  
 
The prognostic value of heart rate according to diabetic and smoking status 
Although both diabetic and nondiabetic patients showed increasing event rates with 
increasing heart rate, the  association between a high heart rate and the risk of the primary 
composite outcome (cardiovascular death or HF hospitalization) appeared to be stronger in 
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nondiabetic than in diabetic patients. For the same outcome, a similar figure was observed 
in nonsmokers as compared with current smokers. The imbalance between 
sympathetic/parasympathetic systems associated with cardiac autonomic neuropathy in 
diabetics and the increased sympathetic outflow induced by smoking are possible 
explanations for these findings (27,28). However, multiple interaction tests were conducted 
with the possibility of a nominally significant interaction occurring by chance alone (29). 
 
Strengths and limitations 
One of the main strengths of the present study is the wide spectrum of LVEF across which 
the prognostic impact of heart rate was investigated. In addition, the modern HF treatment 
used in the CHARM Program, especially beta-blockers, in more than half of the patients, 
makes our results more generalizable to real clinical practice, compared with previous 
reports (5,20). Some limitations of the present analysis should also be acknowledged. We 
relied on investigator-reported baseline  heart rate, which was probably measured in 
different ways, at different times of day and under different circumstances. Estimation of 
the average ventricular rate in patients with atrial fibrillation was probably less reliable than 
measurement of heart rate in those in sinus rhythm. Similarly, patients were classified as 
having AF or no AF according to the investigator interpretation of their baseline ECG. In 
addition, we did not use serial assessments of heart rate over time for the prediction of risk.  
 
Conclusions 
In patients with stable chronic symptomatic HF and without AF, resting heart rate is a 
powerful predictor of mortality and cardiovascular outcomes, irrespective of LVEF, 
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treatment with beta-blockers and other important prognostic factors. This easily measured 
clinical variable could be used in the risk stratification of these patients in everyday clinical 
practice. 
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Figure Legends 
 
Figure 1. Kaplan-Meier survival analysis according to baseline heart rate. 
 Event curves for all-cause mortality [A] and for the composite outcome of 
cardiovascular (CV) death or hospitalization for worsening heart failure (WHFH) [B] 
according to tertiles of baseline heart rate in the overall CHARM population. T = tertile. 
 
Figure 2.  Kaplan-Meier survival analysis according to baseline heart rate, stratified by beta-
blocker use at baseline.  
 Event curves for all-cause mortality [A] and for the composite outcome of 
cardiovascular (CV) death or hospitalization for worsening heart failure (WHFH) [B] 
according to tertiles of baseline heart rate, stratified by beta-blocker use at baseline 
(dashed line = no beta-blocker use at randomization, continuous line = beta blocker use 
at randomization) in the overall CHARM population. P value refers to the test for 
interaction between baseline heart rate and beta-blocker use at baseline. T = tertile. 
 
Figure 3. Event rates in patients with preserved and reduced LVEF according to baseline heart 
rate. 
 All-cause mortality [A] and cardiovascular (CV) death or hospitalization for worsening 
heart failure (WHFH) [B] event rates (per 100-patient years) according to tertiles of 
baseline heart rate in patients with preserved (blue) and reduced (red) left ventricular 
ejection fraction.  LVEF = left ventricular ejection fraction; T = tertile. 
 
Figure 4. Association between baseline heart rate and outcomes by subgroups of LVEF. 
Unadjusted hazard ratios and 95% confidence intervals for all-cause mortality [A] and 
for cardiovascular death or hospitalization for worsening heart failure [B] across tertiles 
of baseline heart rate; p values for interaction between heart rate and left ventricular 
ejection fraction treated as linear continuous variables are shown. CI = confidence 
interval; HR = hazard ratio; T = tertile. 
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Figure 5. Association between baseline heart rate and outcomes by baseline cardiac rhythm.  
Unadjusted hazard ratios and 95% confidence intervals for all-cause mortality [A] and 
for cardiovascular death or hospitalization for worsening heart failure [B] across tertiles 
of baseline heart rate;  p values for interaction between heart rate treated as a linear 
continuous variable and baseline rhythm (sinus rhythm vs. atrial fibrillation) are shown. 
CI = confidence interval; HR = hazard ratio; T = tertile. 
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Table 1. Baseline characteristics of the overall CHARM population according to group 
defined by tertiles of baseline heart rate 
 
 Heart rate group at baseline (bmp)  
 T1  
N = 2553 
(33.6%) 
T2  
N = 2689 
(35.4%) 
T3  
N = 2355 
(31.0%) 
 
 
p-value  
Median heart rate (IQR) 60 (57, 64) 72 (70, 75) 85 (80, 91) for trend 
Patient’s characteristics     
Median age(IQR) 67 (59, 74) 67 (58, 74) 65 (57, 73) <0.001 
   ≥75 years 609 (23.9) 625 (23.2) 503 (21.4) 0.04 
Female 692 (27.1) 905 (33.7) 802 (34.1) <0.001 
LVEF (%) 38 (30, 50) 37 (28, 50) 35 (25, 47) <0.001 
NYHA class 
II 
III/IV 
 
1260 (49.4) 
1293 (50.7) 
 
1202 (44.7) 
1487 (55.3) 
 
953 (40.5) 
1402 (59.5) 
 
 
<0.001 
Atrial fibrillation on ECG 283 (11.1) 398 (14.8) 467 (19.8) <0.001 
Blood pressure (mmHg) 
Systolic 
Diastolic 
 
130 (118, 142) 
75 (70, 80) 
 
130 (120, 142) 
80 (70, 84) 
 
130 (118, 144) 
80 (70, 85) 
 
0.22 
<0.001 
     
Medical history     
Current smoking 305 (11.9) 378 (14.1) 431 (18.3) 0.008 
Diabetes mellitus 601 (23.5) 789 (29.3) 772 (32.8) <0.001 
Hypertension 1365 (53.5) 1529 (56.9) 1290 (54.8) 0.33 
Hospital admission for HF 1691 (66.2) 1945 (72.3) 1789 (76.0) <0.001 
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Myocardial infarction 1510 (59.2) 1433 (53.3) 1059 (45.0) <0.001 
Stroke 238 (9.3) 238 (8.9) 187 (7.9) 0.09 
History of atrial fibrillation 673 (26.4) 746 (27.7) 664 (28.2) 0.15 
     
Medical treatment     
ACE inhibitors 1054 (41.3) 1098 (40.8) 973 (41.3) 0.99 
Β-blockers 1769 (69.3) 1445 (53.7) 988 (42.0) <0.001 
Diuretics 2031 (79.6) 2202 (81.9) 2051 (87.1) <0.001 
Spironolactone 369 (14.5) 432 (16.1) 470 (20.0) <0.001 
Digoxin/digitalis glycosides 962 (37.7) 1156 (43.0) 1136 (48.2) <0.001 
     
 
 
ACE = angiotensin converting enzyme; BMP = beats per minute; HF = heart failure; IQR = 
interquartile range; LVEF = left ventricular ejection fraction; NYHA = New York Heart 
Association; T = tertile. 
 
31 
 
Table 2. Baseline characteristics according to group defined by tertiles of baseline heart rate in patients with reduced and preserved LVEF. 
 
 Reduced LVEF  Preserved LVEF 
 T1 
N = 1414 
(30.9%) 
T2 
N = 1617 
(35.3%) 
T3 
N = 1545 
(33.8%) 
 
 
p-value  
 T1 
N = 1060 
(35.1%) 
T2 
N = 1037 
(34.3%) 
T3 
N = 924 
(30.6%) 
 
 
p-value  
Median heart rate (IQR) 60 (58, 64) 72 (70, 76) 86 (80, 92) for trend  60 (56, 63) 71 (68, 74) 84 (80, 90) for trend 
Patient’s characteristics          
Median age(IQR) 66 (58, 74) 67 (58, 73) 65 (56, 72) <0.001  68 (61, 75) 68 (59, 75) 68 (58, 75) 0.03 
   ≥75 years 311 (22.0) 329 (20.4) 290 (18.8) 0.03  281 (26.5) 275 (26.5) 251 (27.2) 0.75 
Female 303 (21.4) 447 (27.6) 438 (28.4) <0.001  360 (34.0) 429 (41.4) 422 (45.7) <0.001 
LVEF (%) 30 (25, 35) 30 (24, 35) 29 (22, 35) <0.001  53 (46, 60) 52 (46, 60) 53 (46, 60) 0.73 
NYHA class 
II 
III/IV 
 
536 (37.9) 
878 (62.1) 
 
561 (34.7) 
1056 (65.3) 
 
483 (31.3) 
1062 (68.7) 
 
 
<0.001 
  
672 (63.4) 
388 (36.6) 
 
630 (60.8) 
407 (39.3) 
 
533 (57.7) 
391 (42.3) 
 
 
0.01 
Blood pressure (mmHg) 
Systolic 
Diastolic 
 
125 (110, 140) 
75 (68, 80) 
 
126 (114, 140) 
77 (70, 80) 
 
128 (113, 140) 
80 (70, 85) 
 
0.09 
<0.001 
  
135 (120, 150) 
78 (70, 82) 
 
135 (120, 150) 
80 (70, 86) 
 
140 (124, 150) 
80 (70, 88) 
 
0.007 
<0.001 
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Medical history          
Current smoking 171 (12.1) 230 (14.2) 304 (19.7) 0.01  127 (12.0) 139 (13.4) 143 (15.5) 0.72 
Diabetes mellitus 311 (22.0) 486 (30.1) 509 (32.9) <0.001  269 (25.4) 297 (28.6) 290 (31.4) 0.003 
Hypertension 650 (46.0) 812 (50.2) 781 (50.6) 0.01  660 (62.3) 690 (66.5) 591 (64.0) 0.39 
Hospital admission for HF 981 (69.4) 1186 (73.4) 1183 (76.6) <0.001  651 (61.4) 736 (71.0) 688 (74.5) <0.001 
Myocardial infarction 917 (64.9) 968 (59.9) 779 (50.4) <0.001  555 (52.4) 459 (44.3) 324 (35.1) <0.001 
Stroke 130 (9.2) 141 (8.7) 124 (8.0) 0.26  98 (9.3) 93 (9.0) 77 (8.3) 0.48 
History of atrial fibrillation 366 (25.9) 444 (27.5) 393 (25.4) 0.76  286 (27.0) 292 (28.2) 302 (32.7) 0.006 
          
Medical treatment          
ACE inhibitors 808 (57.1) 903 (55.8) 838 (54.2) 0.11  226 (21.3) 192 (18.5) 158 (17.1) 0.02 
Β-blockers 984 (69.6) 868 (53.7) 667 (43.2) <0.001  736 (69.4) 578 (55.7) 369 (39.9) <0.001 
Diuretics 1206 (85.3) 1411 (87.3) 1410 (91.3) <0.001  764 (72.1) 760 (73.3) 733 (79.3) <0.001 
Spironolactone 247 (17.5) 303 (18.7) 370 (24.0) <0.001  112 (10.6) 126 (12.2) 113 (12.2) 0.24 
Digoxin/digitalis glycosides 699 (49.4) 845 (52.3) 868 (56.2) <0.001  241 (22.7) 293 (28.3) 308 (33.3) <0.001 
          
 
ACE = angiotensin converting enzyme; BMP = beats per minute; HF = heart failure; IQR = interquartile range; LVEF = left ventricular ejection 
fraction; NYHA = New York Heart Association; T = tertile. 
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Table 3. Baseline characteristics according to group defined by tertiles of baseline heart rate in patients without and with atrial fibrillation. 
 
 No Atrial fibrillation at randomization  Atrial fibrillation at randomization 
 
 
T1 
N = 2270 
(35.2%) 
T2 
N = 2058 
(31.9%) 
T3 
N = 2121 
(32.9%) 
 
 
p-value  
 T1 
N = 453 
(39.5%) 
T2 
N = 352 
(30.7%) 
T3 
N = 343 
(29.9%) 
 
 
p-value 
Median heart rate (IQR) 60 (57, 64) 72 (70, 74) 84 (80, 90) for trend  64 (60, 68) 76 (72, 80) 90 (86, 100) for trend 
Patient’s characteristics          
Median age(IQR) 67 (59, 74) 67 (57, 73) 65 (56, 72) <0.001  70 (64, 76) 70 (63, 77) 69 (61, 75) 0.009 
   ≥75 years 519 (22.9) 429 (20.9) 414 (19.5) 0.007  149 (32.9) 125 (35.5) 101 (29.5) 0.36 
Female 636 (28.0) 684 (33.2) 731 (34.5) <0.001  109 (24.1) 127 (36.1) 112 (32.7) 0.005 
LVEF (%) 38 (30, 50) 37 (28, 50) 35 (25, 46) <0.001  37 (28, 50) 38 (29, 51) 38 (29, 50) 0.94 
NYHA class 
II 
III/IV 
 
1151 (50.7) 
1119 (49.3) 
 
949 (46.1) 
1109 (53.9) 
 
853 (40.2) 
1268 (59.8) 
 
 
<0.001 
  
174 (38.4) 
279 (61.6) 
 
136 (38.6) 
216 (61.4) 
 
152 (44.3) 
191 (55.7) 
 
 
0.11 
Blood pressure (mmHg) 
Systolic 
Diastolic 
 
130 (120, 142) 
75 (70, 80) 
 
130 (120, 142) 
80 (70, 84) 
 
130 (118, 144) 
80 (70, 85) 
 
0.57 
<0.001 
  
130 (112, 140) 
75 (70, 82) 
 
130 (120, 145) 
80 (70, 85) 
 
130 (120, 145) 
80 (70, 90) 
 
0.005 
<0.001 
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Medical history          
Current smoking 276 (12.2) 310 (15.1) 390 (18.4) 0.001  44 (9.7) 38 (10.8) 56 (16.3) 0.93 
Diabetes mellitus 531 (23.4) 613 (29.8) 732 (34.5) <0.001  112 (24.7) 91 (25.9) 83 (24.2) 0.90 
Hypertension 1217 (53.6) 1153 (56.0) 1174 (55.4) 0.24  247 (54.5) 201 (57.1) 192 (56.0) 0.65 
Hospital admission for HF 1466 (64.6) 1458 (70.9) 1572 (74.1) <0.001  358 (79.0) 291 (82.7) 280 (81.6) 0.32 
Myocardial infarction 1393 (61.4) 1176 (57.1) 1024 (48.3) <0.001  183 (40.4) 109 (31.0) 117 (34.1) 0.05 
Stroke 211 (9.3) 165 (8.0) 166 (7.8) 0.08  49 (10.8) 37 (10.5) 35 (10.2) 0.78 
History of atrial fibrillation 406 (17.9) 328 (15.9) 252 (11.9) <0.001  432 (95.4) 335 (95.2) 330 (96.2) 0.59 
          
Medical treatment          
ACE inhibitors 911 (40.1) 829 (40.3) 911 (43.0) 0.06  227 (50.1) 128 (36.4) 119 (34.7) <0.001 
Β-blockers 1627 (71.7) 1143 (55.5) 884 (41.7) <0.001  229 (50.6) 156 (44.3) 163 (47.5) 0.34 
Diuretics 1764 (77.7) 1638 (79.6) 1820 (85.8) <0.001  422 (93.2) 324 (92.1) 316 (92.1) 0.57 
Spironolactone 311 (13.7) 297 (14.4) 405 (19.1) <0.001  105 (23.2) 83 (23.6) 70 (20.4) 0.38 
Digoxin/digitalis glycosides 754 (33.2) 773 (37.6) 881 (41.5) <0.001  330 (72.9) 265 (75.3) 251 (73.2) 0.87 
          
 
ACE = angiotensin converting enzyme; BMP = beats per minute; HF = heart failure; IQR = interquartile range; LVEF = left ventricular ejection 
fraction; NYHA = New York Heart Association; T = tertile. 
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Table 4. Event rates, adjusted hazard ratios across tertiles of heart rate and adjusted hazard ratios for each 10-beat increase in baseline heart 
rate for all-cause mortality and for cardiovascular death or hospitalization for worsening heart failure 
 
 All-cause mortality  CV-death or hospitalization for HF 
 
Event rates and 95% CI 
per 100 patient-years 
HR and 95% CI* 
 
HR and 95% CI per 
10 bpm increase* 
 Event rates and 95% CI 
per 100 patient-years 
HR and 95% CI* 
 
HR and 95% CI per 
10 bpm increase* 
Overall 
  T1 
  T2 
  T3 
All patients 
 
 
7.2 (6.6 – 7.8) 
8.3 (7.7 – 9.0) 
10.2 (9.4 – 11.0) 
- 
 
1.00 
1.07 (0.95 – 1.20) 
1.27 (1.13 – 1.43) 
- 
 
 
 
 
1.06 (1.02 – 1.10) 
  
10.3 (9.5 – 11.1) 
12.8 (12.0 – 13.7) 
15.3 (14.3 – 16.4) 
- 
 
1.00 
1.11 (1.01 – 1.23) 
1.23 (1.11 – 1.36) 
- 
 
 
 
 
1.07 (1.04 – 1.10) 
Reduced LVEF 
  T1 
  T2 
  T3 
All patients 
 
 
 
8.9 (8.0 – 9.8) 
10.5 (9.6 – 11.5) 
12.2 (11.2 – 13.3) 
- 
 
1.00 
1.10 (0.96 – 1.27) 
1.26 (1.09 – 1.45) 
- 
 
 
 
 
1.06 (1.02 – 1.10) 
  
12.5 (11.5 – 13.7) 
15.8 (14.6 – 17.1) 
18.4 (17.0 – 19.8) 
- 
 
1.00 
1.15 (1.01 – 1.30) 
1.25 (1.11 – 1.42) 
- 
 
 
 
 
1.07 (1.03 – 1.10) 
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Preserved LVEF 
  T1 
  T2 
  T3 
All patients 
 
 
5.0 (4.3 – 5.8) 
5.2 (4.4 – 6.1) 
6.3 (5.4 – 7.3) 
- 
 
1.00 
1.05 (0.84 – 1.32) 
1.25 (0.99 – 1.58) 
- 
 
 
 
 
1.05 (0.98 – 1.12) 
  
7.4 (6.5 – 8.4) 
8.9 (7.8 – 10.0) 
9.8 (8.6 – 11.1) 
- 
 
1.00 
1.14 (0.94 – 1.37) 
1.14 (0.93 – 1.38) 
- 
 
 
 
 
1.06 (1.00 – 1.12) 
No Atrial fibrillation 
  T1 
  T2 
  T3 
All patients 
 
 
6.7 (6.1 – 7.4) 
7.7 (7.0 – 8.5) 
9.5 (8.8 – 10.4) 
- 
 
1.00 
1.08 (0.94 – 1.23) 
1.26 (1.10 – 1.43) 
- 
 
 
 
 
1.08 (1.04 – 1.12) 
  
9.4 (8.7 – 10.2) 
12.0 (11.1 – 13.0) 
15.0 (14.0 – 16.1) 
- 
 
1.00 
1.14 (1.02 – 1.28) 
1.28 (1.14 – 1.44) 
- 
 
 
 
 
1.10 (1.06 – 1.13) 
Atrial fibrillation 
  T1 
  T2 
  T3 
All patients 
 
11.6 (9.8 – 13.6) 
13.0 (10.9 – 15.5) 
10.3 (8.4 – 12.5) 
- 
 
1.00 
1.15 (0.90 – 1.48) 
0.97 (0.75 – 1.26) 
- 
 
 
 
 
0.97 (0.90 – 1-05) 
  
18.3 (15.9 – 21.1) 
17.5 (14.9 – 20.6) 
14.3 (12.0 – 17.1) 
- 
 
1.00 
0.97 (0.78 – 1.21) 
0.85 (0.67 – 1.07) 
- 
 
 
 
 
0.95 (0.89 – 1.02) 
 
 
bpm = beats per minute;  CI = confidence interval;  LVEF = left ventricular ejection fraction;  HF = Heart Failure;  HR = hazard ratio; T = tertile. 
 
*  Model is adjusted for age, LVEF, diabetes, BMI, previous HF hospitalization, gender, NYHA class, radiologic cardiomegaly, diastolic blood 
pressure, randomized treatment and beta-blocker use at baseline. 
37 
 
Figure 1.  
 
0.00
0.10
0.20
0.30
0.40
Pr
ob
ab
ili
ty
 o
f a
ll-
ca
us
e 
m
or
ta
lit
y
2355 2239 2127 2019 1922 1755 1338 585T3
2689 2582 2501 2412 2306 2109 1634 686T2
2553 2478 2405 2323 2230 2073 1565 663T1
Number at risk
0 6 12 18 24 30 36 42
Months
T3
T2
T1
A
 
 
0.00
0.10
0.20
0.30
0.40
Pr
ob
ab
ili
ty
 o
f C
V 
de
at
h 
or
 W
H
FH
2355 2065 1899 1760 1632 1468 1116 495T3
2689 2439 2276 2142 2007 1796 1372 565T2
2553 2370 2244 2127 2006 1835 1390 566T1
Number at risk
0 6 12 18 24 30 36 42
Months
T3
T2
T1
B
 
 
 
38 
 
Figure 2. 
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Figure 4. 
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